Terms: = Prostate cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Clinical Outcome
4 results:
1. Expression of pd-l1 in tumor-associated nerves correlates with reduced CD8
Mo RJ; Han ZD; Liang YK; Ye JH; Wu SL; Lin SX; Zhang YQ; Song SD; Jiang FN; Zhong WD; Wu CL
Int J Cancer; 2019 Jun; 144(12):3099-3110. PubMed ID: 30537104
[TBL] [Abstract] [Full Text] [Related]
2. Radiotherapy with the anti-programmed cell death ligand-1 immune checkpoint blocker avelumab: acute toxicities in triple-negative breast cancer.
La Rocca E; Dispinzieri M; Lozza L; Mariani G; Di Cosimo S; Gennaro M; Valdagni R; De Santis MC
Med Oncol; 2018 Nov; 36(1):4. PubMed ID: 30443687
[TBL] [Abstract] [Full Text] [Related]
3. Systematic Review of Immune Checkpoint Inhibition in Urological cancers.
Rijnders M; de Wit R; Boormans JL; Lolkema MPJ; van der Veldt AAM
Eur Urol; 2017 Sep; 72(3):411-423. PubMed ID: 28645491
[TBL] [Abstract] [Full Text] [Related]
4. b7-h3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy.
Roth TJ; Sheinin Y; Lohse CM; Kuntz SM; Frigola X; Inman BA; Krambeck AE; McKenney ME; Karnes RJ; Blute ML; Cheville JC; Sebo TJ; Kwon ED
Cancer Res; 2007 Aug; 67(16):7893-900. PubMed ID: 17686830
[TBL] [Abstract] [Full Text] [Related]
